Clinical trials: COPD
Chronic Obstructive Pulmonary Disease
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
The purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to Advair Diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and…
- Trial name
- NCT00403286
- Testing
- Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate
- Where
- 49 sites in United States
- Volunteers
- 457 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
This study compared the correct use of and patient preference for two drug delivery systems (inhalers) in patients with COPD
- Trial name
- INHALATOR (NCT01727024)
- Testing
- Tiotropium, Indacaterol
- Where
- 10 sites in Brazil
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT02242279
- Testing
- BEA 2180 BR, Tiotropium
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients
The purpose of this study is to evaluate the efficacy and safety of CHF 5259 (glycopyrrolate bromide) for the treatment of COPD patients.
- Trial name
- Trigon (NCT02189577)
- Testing
- CHF 5259
- Where
- 29 sites in Bulgaria, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lung Diseases, Pulmonary Disease, Chronic Obstructive
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an…
- Trial name
- NCT00132730
- Testing
- MK-0873 2.5 mg, MK-0873 1.25 mg, MK-0873 0.75 mg
- Volunteers
- 604 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD Exacerbation, CHF
Evaluation of the Multidimensional Dyspnea Profile (MDP)
Aim of this multicenter prospective cohort study is the evaluation of the multidimensional qualities of dyspnea in a number of diseases using the Multidimensional Dyspnea Profile (Banzett et al, ERJ 2015).
- Conditions
- COPD Exacerbation, CHF, OSA, COPD
- Trial name
- NCT04090671
- Testing
- Multidimensional Dyspnea Profile
- Where
- 4 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Pulmonary Disease, Chronic Obstructive
Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease
The objective of this study was to compare the bronchodilator efficacy and safety of ipratropium bromide HFA-134a inhalation aerosol and marketed, Atrovent® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02260011
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent® CFC inhalation aerosol
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Asthma, Pulmonary Disease, Chronic Obstructive
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
The purpose of this study is to characterize the clinical, physiologic, and molecular profiles of healthy participants, participants with mild, moderate, and severe asthma; and participants with moderate to severe Chronic…
- Trial name
- NCT01274507
- Testing
- Medical tests
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 328 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.
- Trial name
- S-1226(8%) (NCT02334553)
- Testing
- S1226(8%)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- SolAeroMed Inc.
COPD
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
- Trial name
- NCT00129831
- Testing
- QAB149
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis
Emphysema
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation.
- Trial name
- NCT00207337
- Testing
- Exhale Drug-Eluting Stent
- Where
- 6 sites in Australia, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- Broncus Technologies
Emphysema
STRIVE Post-Market Registry Study
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
- Trial name
- NCT04302272
- Testing
- Spiration Valve System (SVS)
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Olympus Corporation of the Americas
Chronic Obstructive Pulmonary Disease
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to establish the prevalence of comorbidities in Italian patients with chronic bronchitis with at least 2 exacerbations per year, and to document the appropriateness of instrumental diagnostic tests…
- Trial name
- PREFER (NCT02100332)
- Where
- Italy
- Volunteers
- 860 people
- Sponsor
- AstraZeneca
COPD
SYMBICORT® in the Treatment of COPD
A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners
- Trial name
- SRP COPD (NCT00564499)
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease
The primary objective of this non-interventional study is to evaluate daily symptom variability in COPD patients. The secondary objectives are; to evaluate effects of COPD symptoms on the morning activities of patients, to…
- Trial name
- NCT01110564
- Where
- 19 sites in Turkey (Türkiye)
- Volunteers
- 515 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD
A prospective observational multi centre research study in GP practices clustered within up to 10 UK Primary care trusts.
- Trial name
- INHALE (NCT02123199)
- Testing
- Indacaterol (Onbrez®) /QAB149
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/UMEC/VI [100/62.5/25 microgram (mcg)]…
- Trial name
- NCT03478683
- Testing
- budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI
- Where
- 57 sites in United States, Czechia and 2 more
- Volunteers
- 729 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD.
- Trial name
- COPD (NCT07363694)
- Testing
- PF-07275315 dose 1, PF-07275315-dose 2, PF-07275315-dose 3
- Where
- 189 sites in United States, Argentina and 16 more
- Volunteers
- 1,156 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled…
- Trial name
- NCT00975195
- Testing
- tiotropium inhalation, salmeterol xinafoate, fluticasone propionate
- Where
- 222 sites in Australia, Belgium and 21 more
- Volunteers
- 2,488 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and…
- Trial name
- PROSPERO (NCT05742802)
- Testing
- Tozorakimab 1, Tozorakimab 2
- Where
- 335 sites in United States, Argentina and 35 more
- Volunteers
- 1,713 people
- Sponsor
- AstraZeneca